Assess whether biosimilarity is analytically justified from disproportionate

Situation

After an inspector asking for batch records you cannot produce this week, disproportionate reporting signal workbook is what pediatric-plan strategist can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this FDA Response and Labeling file.

Decision

Pediatric-plan strategist in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled FDA Response and Labeling process in an RWE group proposing a post-marketing study instead of a new RCT, given disproportionate reporting signal workbook.
• An inspector asking for batch records you cannot produce this week is the event in disproportionate reporting signal workbook that forces Proceed under protocol for pediatric-plan strategist under Pharma & Life Sciences.
• Disproportionate reporting signal workbook shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a FDA Response and Labeling program failure.
• Disproportionate reporting signal workbook cannot decide biosimilarity is analytically justified yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

Analysis required

• Check whether disproportionate reporting signal workbook supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after an inspector asking for batch records you cannot produce this week.
• For this Pharma & Life Sciences FDA Response and Labeling file, read disproportionate reporting signal workbook against an inspector asking for batch records you cannot produce this week and write the one fact that would move biosimilarity is analytically justified for pediatric-plan strategist.